Open AccessThe incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections
Author(s) -
David B. Huang,
Cédric Charrier,
Chloé Le Bras,
Stephen Hawser,
Stephanie Noviello
Publication year - 2019
Publication title -
journal of medical microbiology/journal of medical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.91
H-Index - 117
eISSN - 1473-5644
pISSN - 0022-2615
DOI - 10.1099/jmm.0.000989
Subject(s) - incidence (geometry) , medicine , dermatology , intensive care medicine , optics , physics
The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml -1 for S. aureus (0.12 µg ml -1 against methicillin-sensitive and 0.25 µg ml -1 against methicillin-resistant S. aureus). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml -1 was 2.0 % (16/790). The clinical outcomes varied by MICs for early clinical response (63-100 %), end of therapy response (81-100 %) and the test of cure response (75-100 %). For microbiological outcomes of these infections, the end of therapy response was 80-100 % and the test of cure response was 88-100 %.